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Abstract
Background: The viral hemorrhagic septicemia virus (VHSV) is one of the most serious fish pathogens. In 2003, a
novel sublineage (genotype IVb) of this deadly virus emerged in the Great Lakes basin causing serious fish kills. We
have previously demonstrated that a DNA plasmid (pcDNA), containing a cytomegalovirus (CMV) promoter and the
viral hemorrhagic septicemia virus (VHSV) genotype IVb glycoprotein (G) gene insert (designated pVHSivb-G) confers
moderate protection in muskellunge (Esox masquinongy), a highly susceptible species upon challenge. In order to
achieve optimal protection, we investigated a number of factors including the incubation time [i.e. the number of
degree days (° days)] before challenge, and viral challenge dose and route. Additionally, we tested if pVHSivb-G
provides protection against VHSV-IVb to less susceptible salmonids such as rainbow trout (Oncorhynchus mykiss),
brown trout (Salmo trutta) and lake trout (Salvelinus namaycush).
Results: An increase in the period lapsed between vaccination and challenge to 1880° days resulted in 95% relative
percent protection (RPS) in muskellunge following a single administration of the pVHSivb-G plasmid and viral
challenge. An RPS of 100% for muskellunge was achieved with a longer incubation period (2400° days) and
in conjunction with a booster dose of the plasmid. The pVHSivb-G vaccine also elicited significant protection
in all three salmonid species, reaching 100% RPS in lake trout following an incubation period of 1001° days
prior to viral challenge. Vaccination with pVHSivb-G was also associated with the development of significant
levels of circulating VHSV-binding antibodies in muskellunge as measured by indirect ELISA, which reached
peak levels 6–7 weeks post-vaccination. Viral shedding in vaccinated survivors was minimal and of transient nature.
Conclusions: The study shows that the pVHSivb-G plasmid can elicit a protective response against the wild virus strain
in a range of species important in recreational and commercial Great Lakes fisheries.
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Background
The emergence of a novel Novirhadovirus, viral
hemorrhagic septicemia virus (VHSV) genotype (IVb) in
the Laurentian Great Lakes basin of North America
alarmed fishery managers and researchers to the conse-
quences its spread could bring to cultured and wild fish
populations [1, 2]. This VHSV sublineage has an unusually
wide host range, infecting 28 fish species, with muskel-
lunge (Esox masquinongy) being the most susceptible spe-
cies documented to date [3–6]. In the Great Lakes basin,
numerous state and federal fish hatcheries are involved in
propagation and stocking of a variety of fish species whose
populations have been drastically suppressed from histor-
ical levels and in some cases are at risk of being endan-
gered [7]. Of these fish stocks, millions of muskellunge
and salmonid fry and fingerlings are annually propagated
and released throughout the basin to support recreational
and commercial fisheries. Salmon, lake sturgeon (Acipen-
ser fulvescens), and muskellunge propagation relies on the
collection of gametes from wild fish, while other programs
[(e.g., rainbow trout (Oncorhynchus mykiss), brown trout
(Salmo trutta), and lake trout (Salvelinus namaycush)]
raise captive broodstocks [8]. Field observations and ex-
perimental studies have clearly demonstrated differing
species susceptibility to VHSV-IVb, with salmonids exhi-
biting low to moderate susceptibility [2, 4, 5]. While the
risks of VHSV-IVb are highest to the basin-wide muskel-
lunge rehabilitation program, there are major concerns
that salmonids may also aid in virus dissemination. This is
particularly true since VHSV-IVb has been previously de-
tected in apparently healthy salmonid species and gametes
(reviewed in Faisal et al. [2]). To date, stringent biosecurity
measures along with regulation of live fish transfer have
successfully prevented VHSV-IVb from infecting hatchery
populations. However, culture practices relying upon gam-
ete collection from wild-fish and the stocking of progeny
in public waters engender risks of VHSV-IVb introduction
into hatcheries and consequently the potential of propa-
gated fish to transmit VHSV-IVb upon stocking [9]. As
a result, there is an urgent need to develop an effica-
cious VHSV vaccine that can protect multiple propa-
gated fish species.
In a previous study, we explored the usefulness of a
DNA-vaccine preparation, incorporating the VHSV-IVb
glycoprotein (G) gene under the control of a human
cytomegalovirus (CMV) promoter in protecting muskel-
lunge upon challenge with the wild virus [10]. In that
study, 539° days following an intramuscular administra-
tion (IM) of the plasmid, fish were immersion challenged
with 105 VHSV-IVb plaque forming units (pfu) mL−1.
While administration of the G gene plasmid elicited the
development of neutralizing antibodies, protection fol-
lowing challenge was moderate, achieving 45% relative
percent survival (RPS) [10]. Encouraged by these results,
the first aim of the present study was to optimize pro-
tective efficacy in vaccinated muskellunge by modifying
a number of factors in the vaccination regimen such as
time between vaccination and challenge, virus challenge
dose, and the number of vaccine doses administered.
We further investigated if vaccinated fish that survive in-
fection were able to mount a humoral immune response
and whether survivors continued to harbor and shed the
VHSV-IVb. The second aim of the study was to deter-
mine if this same vaccine preparation could also be used
to protect three representative genera of salmonids
found in the Great Lakes basin: rainbow trout, brown
trout and lake trout.
Methods
Fish
Two groups of muskellunge were used in this study. The
first group of muskellunge, used in the first two muskel-
lunge trials (MUS-1 and MUS-2), was obtained 16 weeks
post-hatch [average 14.2 cm (SD = 1.4) fork length,
11.9 g (SD = 3.8)] from Chautauqua State Fish Hatchery
(New York Department of Environmental Conservation,
Chautauqua, NY). The second group of muskellunge,
used in the third trial (MUS-3), was obtained 14 weeks
post-hatch [average 15.6 cm (SD = 0.8) fork length,
16.0 g (SD = 1.1)] from Wolf Lake State Fish Hatchery
[Michigan Department of Natural Resources (MDNR),
Mattawan, MI)]. Rainbow trout (land-locked Eagle Lake
morphotype) were obtained 12 weeks post-hatch [aver-
age of 3.6 cm (SD = 0.4) fork length, 0.7 g (SD = 0.3)]
from the Oden State Fish Hatchery (MDNR, Alanson,
MI). Brown trout (Gilchrest morphotype) were obtained
16 weeks post-hatch [average 7.5 cm (SD = 1.1) fork
length, 4.2 g (SD = 1.7)] also from the Oden State Fish
Hatchery. Lake trout (Lake Superior strain) were ob-
tained 18 weeks post-hatch [average 17.6 cm (SD = 1.4)
fork length, 24.1 g (SD = 6.5)] from Marquette State Fish
Hatchery (MDNR, Marquette, MI).
All fish were certified to be free of important diseases
according to World Organization for Animal Health
(OIE) testing guidelines [11]. Fish were acclimated in 500-
L circular fiberglass tanks in a continuous flow-through
system with facility-chilled well water (11 °C) and supple-
mental aeration. Vaccination and experimental challenges
were performed at the Michigan State University Research
Containment Facility (East Lansing, MI). Muskellunge
were fed live fathead minnows (Pimephales promelas) ob-
tained from Anderson Farms Inc. (Lonoke, AR) that were
certified free of important diseases according to OIE
guidelines. An additional 60 fathead minnows were
necropsied and underwent additional testing accord-
ing to the American Fisheries Society guidelines [12].
Rainbow trout and lake trout were fed Skretting dry
pellets (Skretting USA; Tooele, UT), while brown
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trout were fed Nelson’s Silver Cup trout feed (Harrietta
Hills, Harrietta, MI). All fish were fed ad libitum through-
out the study except for muskellunge during the 1st week
post viral challenge when minnows were withheld. Two
weeks prior to immunization, fish were randomly dis-
tributed among 72-L polyethylene flow-through tanks
(Pentair Aquatic Eco-Systems, Apopka, FL) with sup-
plemental aeration.
Virus and cell culture
The VHSV genotype IVb isolate used in this study was
the Great Lakes index strain MI03 [1]. The isolate has
been maintained by continuous subculture in the cell
line epithelioma papulosum cyprini (EPC). The EPC cell
line was maintained and subcultured in 150-cm2 tissue
culture flasks (Corning Inc., Corning, NY) at 25 °C using
a basal media of Earle’s salt-based minimal essential
medium (MEM) (Invitrogen Corp., Carlsbad, CA) and
supplemented with 29.2 mg ml−1 L-glutamine (Invitro-
gen), penicillin (100 IU mL−1) (Invitrogen), streptomycin
(0.1 mg mL−1) (Invitrogen), 10% fetal bovine serum
(Gemini Bio Products, West Sacramento, CA), and so-
dium bicarbonate (7.5% w/v) (Sigma, St. Louis, MO). Vi-
able viral concentrations were determined using plaque
assay on EPC cell line using polyethylene glycol and a
methylcellulose overlay [13, 14]. Virus was then ali-
quoted into cryogenic vials (Corning) for one time use
and stored at − 80 °C.
Construction of pVHSivb-G plasmid
The pcDNA_3.1 (+) is a commercially available vector
containing the human CMV immediate-early promoter.
The DNA vaccine construct containing the VHSV-IVb
glycoprotein gene (designated pVHSivb-G, [10]) was
modeled after successful DNA vaccines against VHSV
genotype I [15, 16] and IHNV [17]. The construction
and production of this plasmid were outsourced to Life
Technologies (Carlsbad, CA). In brief, an EcoRI restric-
tion site (G/AATTC) followed by a kozak consensus
sequence terminating with the first amino acid of the
complete MI03GL VHSV-IVb isolate glycoprotein
gene (1524 bp) was synthesized; an XbaI restriction
site (T/CTAGA) was then added following the 3′ ter-
mination codon. The assembled fragment was then
digested using the described endonucleases and sub-
cloned into the eukaryotic expression vector pcDNA
3.1 (+) (Invitrogen). The plasmid was transformed and
propagated into K12 Escherichia coli. Sequencing con-
firmed the correct glycoprotein gene sequence and
orientation. The pcDNA 3.1 (+) vector without the
glycoprotein gene was similarly propagated and used as
a negative (mock) control. Both plasmids were sus-
pended in sterile PBS and stored at − 80 °C until use.
The final products were designated pVHSivb-G and
pcDNA (mock).
Vaccination and challenge
Immediately prior to vaccination, all plasmid vectors were
thawed and diluted to 10 μg in 100 μL sterile PBS. Ran-
domly selected fish were anesthetized with 0.1 g L−1 of tri-
caine methanesulfonate (MS-222) (Western Chemical
Inc., Ferndale, WA) and buffered with 0.3 g L−1 sodium
bicarbonate. All fish were immunized IM with 10 μg of
plasmid DNA in the left epaxial musculature. Nine trials
took place which varied in number of °days (540 to 2400)
within which fish were allowed to mount immune re-
sponse prior to challenge. For all the trials using the three
salmonid species, fish were allowed to mount an immune
response for 1001° days prior to challenge. Additionally,
booster doses were applied following 940° days in MUS-2
and MUS-3, and to a subset of individuals following 546°
days in the salmonids trials. Fish were VHSV challenged
using either intraperitoneal injection or immersion chal-
lenge. In trials using immersion challenge (see below),
viral challenges were conducted in glass aquaria contain-
ing 32 L of chilled well water and supplemental external
aeration. Fish were challenged via immersion in static
water containing infectious virus for 60 min. All negative
challenge controls were similarly challenged with minimal
essential media. After 60 min, fish were returned to their
respective tanks and monitored daily for morbidity and
mortality for 28 days. Kidney, spleen and heart samples
were collected from all mortalities, and inoculated onto
EPC monolayers. After 14 days, supernatant was removed,
frozen at − 80 °C, thawed at centrifuged at 2700 g for
15 min at 4 °C. Supernatant was then re-infected onto
fresh EPC monolayer and incubated for 14 days before be-
ing examined for viral cytopathic effect (CPE). RNA from
suspicious samples was then extracted using the QIAamp
Viral RNA kit and following the manufacturer’s in-
structions. The presence of VHSV was confirmed
using real-time reverse transcription polymerase chain
reaction (RT-qPCR) assay specific for VHSV [18, 19].
Muskellunge trials
In the first muskellunge trial (MUS-1), muskellunge were
given a single 10 μg administration of either pVHSivb-G
or pcDNA plasmids (n = 20 plasmid−1) and allowed to
mount an immune response for 1880° days (24 weeks at
11 °C). Fish were divided into 2 tanks containing 10 fish
each per preparation. An additional tank containing 10
muskellunge for each treatment was maintained through-
out the study as non-infected controls. Experimental tanks
were immersion challenged with 2 × 103 pfu mL−1.
The second muskellunge trial (MUS-2) was identical
to MUS-1 except after 940° days (12 weeks in 11 °C
water), a booster dose of 10 μg of their respective
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plasmid was administered to each fish. Following a sec-
ond period of 940° days, fish were immersion challenged
with 2 × 103 pfu mL−1 VHSV-IVb.
This third muskellunge trial (MUS-3) was nearly iden-
tical to that of MUS-2 except that fish were challenged
1460° days (an additional 520° days) following booster
administration. Muskellunge therefore had a total of
2400° days to mount an immune response. Experimental
tanks were challenged with 2 × 103 pfu mL−1.
Rainbow trout trials
The two rainbow trout trials (RBT-1, RBT-2) differed in
conditions only in the VHSV challenge route. In both
trials, fish were immunized IM with the pVHSivb-G or
pcDNA plasmids (RBT-1: n = 39 [pVHSivb-G] and 29
[pcDNA]; RBT-2: n = 48 [pVHSivb-G] and 35 [pcDNA]).
Fish from each treatment were returned to separate 72-
L tanks and maintained throughout the study. After 546°
days (6 weeks in 13 °C water), a portion of the pVHSivb-
G vaccinated fish were administered a 10 μg booster
dose (n = 13 [RBT-1] and 31 [RBT-2] respectively). Rain-
bow trout were then allowed to build an immune response
for an additional 455° days prior to challenge (1001° days
or 11 weeks at 13 °C post initial vaccination). Fish from
RBT-1 were anesthetized and challenged by intra-
peritoneal (IP) injection with 9.5 × 105 pfu in 100 μL of
sterile PBS. The negative control tank received sterile PBS.
Fish from RBT-2 were challenged by immersion with
9.5 × 104 pfu mL−1.
Brown trout trials
Trials with brown trout (BNT-1, BNT-2) were the same as
rainbow trout trials in respect to conditions and viral
challenge. Brown trout were immunized IM with
10 μg of pVHSivb-G or pcDNA plasmids (BNT-1: n = 56
[pVHSivb-G] and 26 [pcDNA]; BNT-2: n = 50 [pVHSivb-
G] and 28 [pcDNA]).. After 546° days (6 weeks in 13 °C
water), (n = 18 [BNT-1] and 25 [BNT-2]), pVHSivb immu-
nized brown trout received a 10 μg booster vaccine dose
and were challenged 455° days later.
Lake trout trials
For comparison purposes, the vaccination regimen in
the two lake trout trials (LAT-1, LAT-2) was identical to
the rainbow and brown trout trials. However, in lake
trout trials the immersion challenge route was not per-
formed, instead we used two IP challenge concentrations.
Lake trout were immunized IM with the pVHSivb-G or
pcDNA plasmids (both trials: n = 61 [pVHSivb-G] and
26 [pcDNA]). After 546° days (6 weeks in 13 °C
water), (n = 27 for both LAT-1 and LAT-2), pVHSivb
immunized lake trout received a 10 μg booster dose.
Fish were challenged 455° days later. Fish in LAT-1
were IP challenged with 9.5 × 105 pfu in 100 μL PBS
while lake trout in LAT-2 were IP challenged with
4.75 × 106 pfu in 500 μL of PBS (i.e., a five-fold
greater VHSV concentration compared to LAT-1),.
Detection of anti-VHSV antibodies in muskellunge sera
using an indirect ELISA procedure
To examine the humoral response associated with the
pVHSivb-G plasmid, blood samples were collected from
27 muskellunge from the Chautauqua State Fish Hatchery
2 weeks prior to immunization. Following collection,
blood was stored at 4 °C for 2 h and centrifuged at 2700 g
for 10 min at 4 °C. Serum was then aliquoted and stored
at − 80 °C until analysis. Muskellunge then received an
intramuscular vaccination of 10 μg of the pVHSivb-G
preparation. Sera was collected and processed as described
above every 2 weeks until 10 weeks (770° days) post vac-
cination. Half of the fish (n = 15) were then immersion
challenged with 2 × 103 pfu mL−1 as previously described.
Sera were then collected from muskellunge 6, 12, 15, 18,
20, 30 and 34 weeks post challenge. All sera samples were
analyzed using a newly developed and optimized muskel-
lunge specific indirect ELISA to assess circulating anti-
VHSV antibodies [20].
Prior to ELISA, serum was heat inactivated at 45 °C
for 30 min. Serum was centrifuged at 2700 g for 10 min.
at 4 °C immediately prior to dilution in a solution of 1%
nonfat dried milk in PBS (dilution of PBS-5% NFDM,
Sigma). Indirect ELISA took place in polystyrene micro-
plates (96-well, Microlon®600 with chimney wells; Grei-
ner Bio-One, Monroe, NC). Plates were sealed during all
incubation periods (SealPlate®; Sigma) and washed 5
times following each incubation period unless otherwise
stated using PBS containing 0.05% Tween 20 (PBS-T20;
Sigma) in an automated microplate washer (BioTek,
4 L × 405™ plate washer; Winooski, VT).
Briefly, microtiter assay plates were coated with
100 μL well−1 of purified VHSV-IVb at 1 μg mL−1 and
incubated overnight (14–16 h) at 4 °C in a humid cham-
ber. After incubation, plates were washed and unbound
sites were blocked with the addition of 430 μL well −1 of
PBS containing 5% NFDM (PBS-5%; Sigma) and incuba-
tion at 37 °C for 1 h. Heat inactivated and diluted test
and control muskellunge sera was then added to dupli-
cate wells at 100 μL well−1. After incubating at 25 °C for
1 h, plates were washed and 100 μL of 1:30,000 dilution
of the 3B10 mouse anti-muskellunge-IgM mAb was
added to all wells and again incubated at 25 °C for 1 h.
Plates were washed and 100 μL of 1:4,000 dilution of a
commercially available goat anti-mouse secondary
horseradish peroxidase (HRP) conjugated antibody (Invi-
trogen) was added to each well and incubated at 25 °C
for 1 h. Plates were developed by the addition of 100 uL
of 0.4 mg mL−1 o-phenylenediamine (Sigma) in phos-
phate citrate buffer (Sigma) containing 3 mM hydrogen
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peroxide (Avantor Performance Materials Inc., Center
Valley, PA). The reaction proceeded for 30 min at 25 °C
in the dark and was stopped with the addition of 50 L of
3 M sulfuric acid (H2SO4; Avantor Performance Mate-
rials). The optical density (OD) was read at 490 nm using
a BioTek, ELx808™ plate reader (BioTek) and the Gen5
software (BioTek). The average value of blank wells was
subtracted from test and control wells prior to analysis.
A threshold of 0.163 was used as the basis for distin-
guishing between presence/absence of circulating anti-
bodies [20].
Assessment of VHSV shedding by vaccinated and
challenged muskellunge
Surviving vaccinated muskellunge from the MUS-2 and
MUS-3 trials were used to examine for the presence of
VHSV shedding. Samples were collected beginning
4 weeks post challenge and every 4 weeks for 28 weeks.
Shedding analysis was conducted using a slightly modi-
fied protocol of that described by Kim and Faisal [21].
Briefly, individual surviving fish were transferred to glass
aquaria containing 4 L of static facility chilled well water
containing supplemental aeration. After 120 min, water
was mixed and a 50 mL water sample was taken and fish
were placed back into their original tanks. Samples were
stored at 4 °C until processing within 24 h. For process-
ing, samples were vortexed and centrifuged at 2700 g, at
4 °C for 10 min. After centrifugation, a viral plaque assay
(VPA) was conducted as previously described. After
6 days, cell monolayers were stained with crystal violet
(Sigma) and 18% formaldehyde (Avantor Performance
Materials Inc.).
Statistical analysis
For muskellunge trials (MUS-1,2,3) Kaplan-Meier sur-
vival estimates and mean time to death accounting for
right censoring of survival data (i.e., mortality did not
occur during the 28 day monitoring period) were calcu-
lated for each tank of fish using PROC LIFETEST in
SAS [22]. Cox proportional hazards frailty models with
tank as a random effect to account for fish deaths within
tanks not being independent were also calculated for all
trials using PROC PHREG in SAS. In all trials, the cu-
mulative mortality was averaged across replicate tanks
when possible for each trial to calculate RPS for each
treatment [23].
RPS ¼ 1− % cumulative mortality of vaccinated
% cumulative mortality of mock vaccinated
 
 100
In muskellunge trials (MUS-1,2,3), significant differ-
ences in cumulative mortality between or among treat-
ments within a trial were tested using t-tests conducted
using PROC TTEST in SAS. While, due to a lack of
replication in the salmonid trials, statistical significance
was analyzed using a conventional two-tailed χ2-test.
The humoral response in pVHSivb-G vaccinated and
challenged muskellunge were initial examined using a
paired t-test and subsequently analyzed using quantile
regression, which allowed us to more fully examine the
conditional relationship of the humoral response over
time. Separate regression models were estimated for post
vaccination and post challenge responses. Conditional
0.50, 0.75, and 0.90 quantile regressions were fit to each
set of data. Quantile regression allows a more thorough
examination of the conditional relationship between
dependent and independent variables; for example, it
can determine if the rate of change in more extreme
values of the dependent variable is different than the
change for central tendency values [24]. For model fit-
ting, OD values were loge transformed with time (i.e.,
post vaccination or post challenge times) up to its third
power used as explanatory variables. The significance of
explanatory variables (i.e., time, square of time, cube of
time) was tested using likelihood ratio tests. If an ex-
planatory variable was not statistically significant, it was
excluded as an explanatory variable and the model was
refit. 95% confidence intervals for parameter estimates
from the quantile regression models were obtained by
resampling with the number of resampling iterations set
at 1,000. Quantile regression models were fit in SAS
using PROC QUANTREG.
Ethics statement
All experiments were conducted in accordance with the
ethical guidelines defined by Michigan State University’s
(MSU) Institutional Animal Care and Use Committee
(AUF 03/14-047-00).
Results
Vaccine efficacy in muskellunge
For the MUS-1 trial, the two replicate tanks of muskel-
lunge that received the pVHSivb-G plasmid experienced
0 and 10% cumulative mortality whereas the pcDNA
plasmid replicates both experienced 100% mortality
(Table 1), resulting in a mean RPS of 95%. The mean
day of death for the pcDNA plasmid treatments was
11.0 (SE = 1.0) and 12.4 (SE = 1.3) whereas the mean day
of death for the pVHSivb-G plasmid treatment was 16.0
(SE = NA) (mean day to death was only calculable for
one tank and standard errors could not be calculated)
(Table 1). The hazard ratio comparing the pVHSivb-G
and pcDNA plasmids estimated from the Cox propor-
tional hazards frailty model was 0.016 (95% confidence
limits: 0.002–0.124), suggesting the pVHSivb-G treatment
significantly reduced the hazard rate for muskellunge
(Table 1). There was a statistically significant difference in
cumulative mortality between the pVHSivb-G and mock
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treatments (t-test: t = −19.00, df = 2, P-value = 0.003). Dur-
ing necropsy, muskellunge exhibited characteristic clinical
signs of acute VHSV infection including extensive petech-
ial to ecchymotic hemorrhage throughout the muscula-
ture, liver, swim bladder and renal mesentery. Numerous
fish exhibited severely pale gills, liver, and heart. VHSV-
IVb was re-isolated from all of the mortalities on the EPC
cell line.
In the second muskellunge trial (MUS-2), replicate
tanks of pVHSivb-G vaccinated muskellunge challenged
2400° days post-vaccination (PV, 940° days post booster
administration) experienced 0 and 30% mortality (Table 1),
with mean day of death of 10.6 (SE = 0.4) days (mean day
of death could not be calculated for the other replicate
since no mortalities occurred). Conversely, the pcDNA
plasmid replicates experienced 100% mortality with mean
day of death of 9.3 (SE = 0.9) and 10.4 (SE = 0.9) days,
resulting in an RPS of 85%. The hazard ratio comparing
the pVHSivb-G and pcDNA mock treatments was 0.063
(95% confidence limits: 0.018–0.223) (Table 1) suggesting
the pVHSivb-G treatment significantly reduced the hazard
rate for muskellunge. Cumulative mortality between the
pVHSivb-G and pcDNA treatments was significantly dif-
ferent (t-test: t = 5.67, df = 2, P-value = 0.030). During nec-
ropsy, mortalities again exhibited distinct signs of acute
VHSV-IVb infection.
In MUS-3, pVHSivb-G vaccinated muskellunge chal-
lenged 2400° days post-vaccination (PV, 940° days post
booster administration) experienced 0% mortality while
the pcDNA mock replicates experienced 100% mortality
resulting in 100% RPS (Table 1). The mean day of death
of the pcDNA replicates were 12.2 (SE = 1.7) and 13.4
(SE = 1.7) days. This was clearly a significant level of
protection. However, the hazard ratio between the treat-
ments could not be calculated because of the lack of
variability in treatment results. Similarly, the lack of vari-
ability in the treatment results resulted in questionable
t-test results with regards to differences in cumulative
mortality (t-test: t =∞, df = 2, P-value < 0.0001) (Table 1).
Vaccine efficacy in salmonids
Mock-vaccinated rainbow trout in RBT-1 experienced
62% cumulative mortality following IP challenge
(Table 2). In contrast, rainbow trout vaccinated with
pVHSivb-G experienced only 30% cumulative mortality
following a single administration and 15% mortality with
two administrations. Significant protection was observed
in G gene treatments, with 57% RPS (χ2 = 6.83, df = 1,
P–value = 0.009) and 75% RPS (χ2 = 7.84, df = 1, P -value
= 0.005) following one or two pVHSivb-G administration
respectively (Table 2). In RBT-2, only 9% mortality of
the mock-vaccinated fish was observed following chal-
lenge by immersion with the virus and none of the
pVHSivb immunized trout died (Table 2). Due to low
mortality experience in rainbow trout using immersion
infection, significant protection was not observed. All
mortalities exhibited clinical signs of VHSV infection
including mild to moderate petechial to ecchymotic
hemorrhage throughout the musculature, liver, swim
bladder and renal mesentery. VHSV was re-isolated
from all of the mortalities.
Table 1 Summary of the three trials conducted using muskellunge (MUS-1, 2, 3)
Fish Cumulative mortality Mean Cumulative Mortality Mean day to death ± SE HR (95%CI) RPS P-value
MUS-1
pVHSivb-G 10 0% 5% NA 0.016 (0.002–0.124) 95% 0.003
pVHSivb-G 10 10%
pcDNA 10 100% 100% 11.7 ± 1.3 NA NA
pcDNA 10 100%
MUS-2
pVHSivb-G 10 30% 15% 10.6 ± 0.4 0.063 (0.018–0.223) 85% 0.030
pVHSivb-G 10 0%
pcDNA 10 100% 100% 9.9 ± 1.0 NA NA
pcDNA 10 100%
MUS-3
pVHSivb-G 10 0% 0% NA NA 100% <0.0001
pVHSivb-G 10 0%
pcDNA 10 100% 100% 12.8 ± 1.8 NA NA
Total number of fish challenged in each trial, mean cumulative % mortality, and mean days to death of each treatment. The table also includes mean day to
death calculated using PROC LIFETEST in SAS [22]. A Cox proportional hazard model was also fitted using SAS to examine the hazard ratio (HR) between
glycoprotein (G) gene and mock-vaccinated counterparts. The relative percent survival (RPS) was calculated between treatments as previously described [23]. The
P-values are from t-tests testing survival differences between the treatments that were conducted using PROC TTEST in SAS
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In the first brown trout trial (BNT-1), mock-vaccinated
brown trout experienced 23% cumulative mortality
(Table 2) following IP challenge. Fish vaccinated with
pVHSivb-G experienced 5% cumulative mortality with a
single administration and 17% cumulative mortality fol-
lowing two administrations resulting in 77% and 28% RPS
respectively. Protection was only significant in the treat-
ment that received a single administration of the
pVHSivb-G plasmid (χ2 = 4.48, df = 1, P -value = 0.034). In
BNT-2, mock-vaccinated brown trout individuals experi-
enced 11% cumulative mortality following immersion
challenge (Table 2). The cumulative mortality of both the
vaccinated treatments was 4% (63% RPS), resulting from
only a single individual dying in both the treatments. Mor-
talities were again too low to determine significant protec-
tion. The virus was isolated from all mortalities, though
brown trout exhibited milder clinical signs of VHSV infec-
tion including less petechial hemorrhage throughout the
liver, swim bladder and renal mesentery.
In LAT-1, the mock-vaccinated lake trout experienced
31% cumulative mortality (Table 2). Meanwhile, not a
single vaccinated individual from G gene treatments suc-
cumbed. Lake trout experienced significant protection
with 100% RPS in both G gene treatments (χ2 = 12.07,
df = 1, P -value = 0.0005 with a single administration),
(χ2 = 9.79, df = 1, P -value = 0.0018 with two administra-
tions). While, in the second lake trout trial (LAT-2),
when IP challenged with a five-fold higher viral concen-
tration, the mock-vaccinated treatment experienced 35%
cumulative mortality while none of the vaccinated fish
died (Table 2), resulting in 100% RPS and significant
protection (χ2 = 13.85, df = 1, P -value = 0.0002 with a
single administration, and χ2 = 11.26, df = 1, P -value =
0.0008 with two administrations). Lake trout mortalities
exhibited clinical signs of VHSV infection as previously
described and VHSV was isolated from all mortalities.
Development of circulating anti-VHSV antibody response
in pVHSivb-G vaccinated muskellunge
Prior to vaccination the OD levels in the 27 naïve
muskellunge were 0.008 (SD = 0.008). Anti-VHSV anti-
bodies did not appear to significantly increased until
measured 28 days following vaccination, at which
point the mean OD value had reached 0.248 (SD =
0.184) (paired t-test: t = 6.18, df = 23, P-value < 0.0001).
Anti-VHSV antibody levels appeared to peak between
42 days [0.315 (SD = 0.313)] and 56 days [(0.3.72 (SD =
0.256)] post exposure. Though, to precisely predict peak
antibody levels and the duration of the secondary anti-
VHSV antibody response following challenge, quantile re-
gression analysis was utilized.
For all evaluated quantiles, the cube of time post-
vaccination (PV) was not statistically significant by likeli-
hood ratio testing and was dropped from the models
(0.50: x2 = 3.30, df = 1, P-value = 0.069; 0.75: x2 = 1.47, df
= 1, P-value = 0.226; 0.90: x2 = 3.80, df = 1, P-value =
0.051). However, the square of time PV was statistically
significant (P-value <0.0001) for all models. The func-
tional form of the quantile regression fitted relationships
for the OD values was similar across the quantiles, and
could perhaps best be characterized as bell-shaped
(Fig. 1). The model corresponding to a 0.90 quantile had
a somewhat steeper relationship then the other models
as a consequence of a few outlying OD values at be-
tween 4 and 10 weeks post-challenge (Table 3). Based on
predicted relationships from the fitted quantile regres-
sion models, OD values would increase to a value 0.163
by 3 to 4.25 weeks depending on the quantile (Fig. 1).
Peak OD values would occur at around 7 weeks post
vaccination, and would then decline back to 0.163 at
around 10 to 11 weeks post vaccinations (Fig. 1).
For the quantile regression models fit to the post chal-
lenge data, the cube of time post-challenge was not






pVHSivb-G 26 26.9% 56.7% 6.83 0.009
pVHSivb-G (2 doses) 13 15.4% 75.2% 7.84 0.005
RBT-2
pcDNA 35 8.6%
pVHSivb-G 17 0.0% 100.0% 1.55 0.214
pVHSivb-G (2 doses) 31 0.0% 100.0% 2.78 0.095
BNT-1
pcDNA 26 23.1%
pVHSivb-G 38 5.3% 77.2% 4.48 0.034
pVHSivb-G (2 doses) 18 16.7% 27.8% 0.27 0.604
BNT-2
pcDNA 28 10.7%
pVHSivb-G 25 4.0% 62.7% 0.85 0.356
pVHSivb-G (2 doses) 25 4.0% 62.7% 0.85 0.356
LAT-1
pcDNA 26 30.7%
pVHSivb-G 34 0.0% 100.0% 12.07 0.0005
pVHSivb-G (2 doses) 27 0.0% 100.0% 9.79 0.0018
LAT-2
pcDNA 26 34.6%
pVHSivb-G 34 0.0% 100.0% 13.85 0.0002
pVHSivb-G (2 doses) 27 0.0% 100.0% 11.26 0.0008
Rainbow trout (RBT-1 and RBT-2), brown trout (BNT-1 and BNT-2) and lake
trout (LAT-1 and LAT-2) vaccine trials. Table includes the number of fish in
each treatment, the cumulative mortality and the relative percent survival
(RPS) and the associated P-value calculated using a two-tailed χ2-test
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statistically significant (0.50: x2 = 2.31, df = 1, P-value =
0.128; 0.75: x2 = 2.01, df = 1, P-value = 0.156; 0.90: x2 =
0.57, df = 1, P-value = 0.449). Similarly, the square of
time post-challenge was not statistically significant (0.50:
x2 = 2.09, df = 1, P-value = 0.148; 0.75: x2 = 2.17, df = 1, P-
value = 0.141; 0.90: x2 = 1.44, df = 1, P-value = 0.231).
Consequently, both terms were dropped from the
models. Time post-challenge was statistically significant
(P-value <0.005) for all models. The fitted relationships
for each of the quantile regression models was suggest-
ive of an exponential decline in OD values with respect
to time (Fig. 2, Table 3), however, this was likely influ-
ence by the lack of observations for the 4 weeks immedi-
ately following challenge. Based on the predicted
relationships from the regression models, OD values
would not be expected to decline to less than the estab-
lish positive/negative threshold (0.163) until between
weeks 45 and 65 post challenge (Fig. 2).
Viral shedding in pVHSivb-G vaccinated survivors
Shedding was assessed in pVHSivb-G vaccinated survi-
vors from MUS-2 beginning 16 weeks post challenge
and MUS-3 beginning 4 weeks post challenge using a
quantitative viral plaque assay. Low level of shedding
Fig. 1 Levels of anti-VHSV antibodies in immunized muskellunge.
Levels of circulating anti-VHSV antibodies of 27 muskellunge for
10 weeks vaccinated with 10 μg of the pVHSivb-G indicated by indirect
ELISA optical density (OD490) values. The predicted relationships from
0.50, 0.75, and 0.90 quantile regression models was fit to the OD490
values as a function of time since vaccination. The dashed lines repre-
sent ±1 SE of the predicted relationships. The cut off value was esti-
mated to be 0.163, above which a sample was considered positive
Table 3 Parameter estimates of quantile regression models fit to loge OD values
Quantile Model output Intercept Time Time × Time
Post-Vaccination
0.5 Estimate −6.037 1.427 −0.102
standard error 0.532 0.193 0.015
95% confidence limits −2.107 1.045–1.809 −0.059
0.75 Estimate −5.34 1.357 −0.097
standard error 0.434 0.165 0.013
95% confidence limits −1.719 1.030–1.683 −0.052
0.9 Estimate −5.82 1.749 −0.129
standard error 0.845 0.323 0.025
95% confidence limits −3.349 1.109–2.389 −0.1
Post-Challenge
0.5 Estimate 1.304 −0.069 NA
standard error 0.187 0.103 NA
95% confidence limits 0.931–1.678 −0.041 NA
0.75 Estimate 1.343 −0.048 NA
standard error 0.224 0.016 NA
95% confidence limits 0.896–1.791 −0.063 NA
0.9 Estimate 1.573 −0.055 NA
standard error 0.317 0.021 NA
95% confidence limits 0.938–2.208 −0.085 NA
Parameter estimates, standard errors, and 95% confidence limits from 0.50, 0.75, and 0.90 quantile regression models fit to loge OD values post pVHSivb-G
immunization (Post Vaccination) and post VHSV challenge (Post Challenge). The fitted regression models for post-vaccination (PV) included weeks PV (Time) and
the square of weeks PV (Time × Time) as explanatory variables. The fitted regression models for post-challenge included weeks post-challenge (Time) as an
explanatory variable
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was detected from a few survivors, with one fish at 4
and 20 weeks post challenge (Fig. 3), and two fish
8 weeks post challenge shedding 104 to 2.0 × 104 pfu
hour−1. Two fish exhibited the maximum shedding con-
centration (105 pfu hour−1) 16 weeks post challenge. No
shedding was detected after 20 weeks post challenge
from any individual. Overall, viral shedding from vacci-
nated survivors appears minimal and transient.
Discussion
Two decades of research have demonstrated that DNA-
based vaccines can be highly effective for conferring pro-
tection against the European VHSV lineage (genotype Ia)
in rainbow trout, a heavily cultured fish species [25–29].
Experimental DNA vaccine preparations have primarily
incorporated the VHSV glycoprotein (G) gene under the
control of a human cytomegalovirus (CMV) promoter
[15, 28–33]. The G gene is targeted as the encoded protein
is necessity for VHSV attachment and cellular internaliza-
tion [30, 34–36]. Studies show that IM administrations of
doses ranging from 1 μg [28, 29] to 10 μg [15] of a plasmid
containing the VHSV glycoprotein (G) gene, followed by
an incubation period of 400-880° days conferred 83–96%
RPS in rainbow trout, when immersion challenged with
104 to 3 × 106 median tissue culture infectious dose
(TCID50) mL
−1 [15, 28, 29]. In our laboratory, when this
protocol was used in muskellunge it did not protect over
half of vaccinated fish upon challenge [10] and therefore
this study was designed. When we increased the period
that vaccinated muskellunge had to mount an immune re-
sponse prior to challenge, this resulted in greater survivor-
ship than the 45% RPS previously demonstrated. It seems
that a longer time post-vaccination is needed to provide
fish sufficient time to develop a protective immune re-
sponse [37]. The fact that vaccinated fish need a relatively
long time to develop a protective response dictates that
the vaccine should be administered in their early life
stages so that they are protected prior to their stocking in
public waters. In muskellunge, the highest RPS (100%)
Fig. 2 Levels of anti-VHSV antibodies in immunized muskellunge
following VHSV challenge. Levels of circulating anti-VHSV antibodies
of 15 muskellunge following vaccinated with 10 μg of the pVHSivb-G
and VHSV immersion challenged [(2 × 103 pfu mL−1) for 60 min]
indicated by indirect ELISA optical density (OD490) values. Predicted
relationships from 0.50, 0.75, and 0.90 quantile regression models fit to
the OD values as a function of time since vaccination. The dashed lines
represent ±1 SE of the predicted relationships. The cut off value was
estimated to be 0.163, above which a sample was considered positive
Fig. 3 VHSV shedding in immunized muskellunge following shedding. Weighted bubble graph displaying the analysis of shedding in pVHSivb-G
vaccinated muskellunge (n = 39) following a VHSV-IVb immersion challenge (2 × 103 pfu mL−1 for 60 min). Viral plaque assays were conducted on
water samples collected from individual surviving muskellunge every 4 weeks until 28 weeks post challenge
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was observed in MUS-3 when muskellunge received two
administrations of the pVHSivb-G preparation, though a
single administration in MUS-2 under otherwise similar
conditions also resulted in a high RPS (95% RPS). It seems
that administration of more than vaccine dose is not ne-
cessary to achieve protection.
In salmonids, we also demonstrated significant protec-
tion in each species following IP challenge, with RPS ran-
ging from 27.8 to 100% in these trials. The 100% RPS
observed in both the lake trout trials is comparable to the
protection previously achieved with DNA preparations
against VHSV-I and a similar novirhabdovirus, IHNV in
rainbow trout [15, 29]. Though, salmonids are less suscep-
tible to genotype IVb, and a high IP viral concentration
was required to elicit mortality and demonstrate protec-
tion. If environmentally realistic concentrations were uti-
lized [38], this would likely result in greater protection
and survivorship then we have documented. RPS varied
based on the administration of either one or two doses of
the pVHSivb-G plasmid; in BNT-1, fish actually experi-
enced greater protection following only one administra-
tion of the plasmid. Also lake trout experienced identical
protection regardless of the number of plasmid adminis-
trations, providing further evidence that a single adminis-
tration of the plasmid elicits sufficient protection.
We further demonstrate several novel aspects of post
vaccine efficacy. For example, the indirect ELISA demon-
strates that the pVHSivb-G plasmid elicited the develop-
ment of a significant circulating VHSV-binding antibody
response in muskellunge, which peaked around 7 weeks
post vaccination. Though, in muskellunge from the previ-
ous study by Millard et al. [10], 7 weeks post vaccination
corresponded with the initial development of a neutraliz-
ing antibody response, with only 1 of 12 vaccinated mus-
kellunge exhibiting neutralizing anti-VHSV antibodies,
though, 4 weeks later 60% of muskellunge exhibited neu-
tralizing antibodies [10]. This discrepancy can be attrib-
uted to the fact the used indirect ELISA employed in this
study detects all binding antibodies generated in response
to the vaccine while neutralization antibody assay measure
only one subset of these antibodies. Though, in this study,
the incubation period and subsequent challenge we uti-
lized with muskellunge did not appear to correspond with
peak anti-VHSV binding antibody levels as indicated by
the ELISA OD values. Peak binding antibodies levels may
not correspond with peak protection; however, the magni-
tude of the humoral response does appear to indicate the
development of an adaptive response and involving long
lived plasma cells (LLPC) [39]. In studies done on rainbow
trout using a non-microbial antigen, it has been demon-
strated that antibodies produced 12–15 weeks following
immunization have a much higher affinity to the antigen
[40]. A similar phenomenon may be taking place in mus-
kellunge thus explaining the significant protection despite
the overall declining antibody levels. Further, in vaccinated
muskellunge, following challenge, we were able to detect a
vigorous secondary response. We were able to predict this
response would to remain at detectable levels for upwards
of 40–50 weeks and is suggestive a prolonged secondary
immune response. The details of the kinetics of the pri-
mary and secondary humoral response provide a valuable
input for future vaccination and release strategies if this
preparation is approved for use in aquaculture. Needless
to say, cell mediated immunity may also play a major role
in protection of vaccinated fish and should be investigated
in future studies.
The finding that some vaccinated muskellunge, while
protected, may also shed VHSV-IVb into the water col-
umn following exposure is troublesome, however, shed-
ding was restricted to a small subset of vaccinated fish
that survived the challenge with a relative high virus dose.
In the aquatic environment, it is highly unlikely that fish
will be exposed to this viral concentration even in VHSV
endemic waters [38]. In general, VHSV shedding in fish
surviving experimental challenge is of a transient nature
[21]. Our data similarly reflects this trend, however, deter-
mination and kinetics of shedding kinetics in vaccinated
and challenged fish should be ascertained. Unfortunately,
all other studies that described vaccine development
against VHSV never addressed shedding as a measure of
post-challenge vaccine evaluation [10, 15, 16, 26–29].
Herein we have demonstrated that the pVHSivb-G
plasmid can elicit significant protection against VHSV-
IVb in several species. Though salmonids are less sus-
ceptible to genotype IVb, obtaining a protective vaccine
will provide researchers and managers with a potent tool
that can be used to limit transmission of VHSV-IVb.
Most recently, we provided evidence that vaccinated
muskellunge can significantly minimize mortalities in
cohabitating naïve fish upon experimental challenge, a
phenomenon which mimics the concept of herd immun-
ity in terrestrial animals [20]. By vaccinating the millions
of propagated salmonid fry and fingerlings prior to
stocking, the Great Lakes hatchery system could be used
to elicit a large-scale “herd immunity” response. With an
overall decrease in the number of naïve-susceptible indi-
viduals being stocked, there would be a corresponding
decreased viral transmission and an indirect protective
effect to other naïve individuals.
Conclusions
In conclusion, the results we have obtained and the vac-
cination model we have developed can be used as a first
step toward providing managers with tool to stop VHSV
dissemination and associated losses. Additionally, the de-
velopment of an efficacious vaccine preparation allows
us to more thoroughly study the nature of immune re-
sponse in teleosts against serious pathogens.
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